The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies

Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
J-M FerrièreA Ravaud

Abstract

New antiangiogenic molecules have proven an advantage in term of survival in metastatic renal cell carcinoma. We describe herein two clinical cases showing the efficacy of antiangiogenic agent in locally advanced or metastatic renal cell carcinoma. In this cases the surgical management has been altered in front of an important tumor necrosis provided by this treatment. The role of antiangiogenic agents as adjuvant or neo adjuvant therapy has not yet been defined precisely. However, these new molecules open new perspectives in the therapeutic field of metastatic renal cell carcinoma notably in case of bulky tumors which appeared difficult to remove surgically at first look or in case of early recurrence after radical nephrectomy.

References

Sep 26, 2007·Expert Review of Anticancer Therapy·David D Thiel, Howard N Winfield

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Surgical Oncology
René A KlaassenTheo Wiggers
Archivos españoles de urología
Miguel Perán TeruelJulio A Virseda Rodríguez
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
D VallböhmerArnulf H Hölscher
Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
C GebertG Gosheger
© 2022 Meta ULC. All rights reserved